Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

24 Jan 2006 07:01

Sopheon PLC24 January 2006 Embargoed: 24 January 2006, 07:00hrs Sopheon Plc ("Sopheon" or the "Company") The Solae Company Chooses Sopheon to Automate Stage-Gate(R) Process and Support Product Portfolio Decision-Making Accolade System Cited for Capacity to Reduce Business Risk Associated withInnovation Sopheon, the international software and services company, announced today thatThe Solae Company has begun deploying Sopheon's Accolade process and productportfolio management system enterprise-wide to enhance its innovation processesand strengthen innovation-related decision-making support. The Solae Company is an alliance between DuPont and Bunge Ltd. It is a globalleader in the research and application of soy-based food ingredients. As partof a plan for enhancing its innovation processes, Solae elected to adoptStage-Gate, the widely used product development methodology. That decision ledto a search for a technology solution that could both automate Stage-Gate andhelp the company more effectively develop and control its product portfolio. The Solae Company chose the Sopheon system after researching a mix of options.Accolade was selected in part because it offered a disciplined process forcapturing, evaluating and managing product and project ideas. Solae also sawvalue in the software's provision of centralized, real-time visibility toproject details and automated "what if" analysis as a way to increase the speedand quality of portfolio decision-making. The company's choice of Accolade wasfurther based on the solution's capacity to integrate with Design for Six Sigma(DFSS) methodologies that are integral to Solae's innovation processes. "Solae has worked hard to earn its reputation for innovation leadership," saidJonathan McIntyre, vice president of research and development at The SolaeCompany. "But true innovation is inherently risky. It involves reaching beyondthe boundaries of what your customers are able to tell you and anticipating whatthey are going to need, sometimes before they even know it. A principal reasonThe Solae Company chose to adopt the Sopheon system is that it brings consistentrigor to our examination of the business risks and opportunities associated witheach project entering our product development pipeline. Sopheon's Accolade is atool that fits into our larger process for risk management, reducing the chanceof investing in products that the market won't value." "Users often point to how Accolade has increased the flow of innovation intotheir developmental pipeline," said Andy Michuda, chief executive officer ofSopheon. "Solae's perspective focuses on the equally important issue ofensuring that the product ideas an organization invests in are those that havethe greatest potential for success. As a proven innovator, they understand thatthe management of new products is all about ability to make the right businessdecisions. Accolade gives users a competitive edge by helping them reduceuncertainty in choosing the product ideas they are going to back with theircritical R&D resources." Sopheon Accolade(R) is a registered trademark of Sopheon plc. Stage-Gate(R) is a registered trademark of the Product Development Institute,Inc. All other trademarks and registered trademarks are the sole property of their respective owners. About The Solae Company The Solae Company is a global innovator in the research and application of soyprotein. It serves food and beverage manufacturers, dietary supplementdevelopers, retailers and consumers in 100 countries worldwide, providing themwith better ingredients for better living. Headquartered in St. Louis, Missouri,the company was formed through an alliance between Bunge Limited (NYSE: BG) andDuPont (NYSE: DD). For more information, please visit www.solae.com. About Sopheon Sopheon (LSE: SPE) is an international provider of software and services thathelp organizations improve the business impact of product development. TheSopheon Accolade(R) product development system automates gate- or phase-basedproduct development processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time-to-market. Sopheon is listed on the AIM Market of the LondonStock Exchange and on the Euronext in the Netherlands. For more information,please visit www.sopheon.com. Press Contacts: Ron Helgeson Bonnie Anderson/Jessica RoeberSopheon Bell Pottinger USA (for Sopheon)Tel.: +1 952 851 7585 Tel.: +1 617 210 4755E-mail: ron.helgeson@sopheon.com E-mail: banderson@bellpottingerusa.com E-mail: jroeber@bellpottingerusa.comAndrew SheaThe Solae Company+1 314 982 1314E-mail: ashea@solae.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.